TX-FLUENCE
7.4.2022 15:02:07 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, released results from its intercanopy lighting research in collaboration with Wageningen University & Research (WUR). Fluence’s research showed that intercanopy lighting treatments at a high intensity combined with top light increased yield in Hi Power and Skyson cucumber cultivars as well as Merlice and Brioso tomato cultivars.
Following Fluence’s multiyear research on the overall effects of broad-spectrum lighting solutions on plant development, Fluence and WUR further investigated the effects of various light distributions and intensities on plant morphology and fruit quality throughout a winter season.
“Growers have used the same benchmarks for vine crop lighting strategies for decades. Those benchmarks were typically derived from crops grown under high-pressure sodium fixtures that limited potential light intensity due to excess heat,” said David Hawley, principal scientist for Fluence. “LEDs virtually eliminate that restriction. As Fluence seeks to explore how to empower growers to be as productive as possible by maximizing their bottom lines, we wanted to investigate not only how higher intensities affect crops, but how crops use energy within the canopy. Our research overwhelmingly showed that intercanopy lighting in tandem with a top light strategy at a higher intensity boosted yields over conventional lighting strategies.”
Fluence and WUR studied cucumbers and tomatoes in the Netherlands under four light treatments: top light only at 250 µmol/m-2 /s-1 , top light and intercanopy lighting at 250 µmol/m-2 /s-1 , top light only at 375 µmol/m-2 /s-1 , and top light and intercanopy lighting at 375 µmol/m-2 /s-1 . Under the treatments with both top light and intercanopy lighting, two-thirds of the total PPFD were applied to the top of the canopy with Fluence’s VYPR luminaire, with the other third applied through Fluence’s VYNE intercanopy light.
Key findings from the studies include:
- Adding intercanopy lighting at the higher total intensity increased cumulative yield in both cucumber cultivars up to 110% compared to the top light-only treatment at the lower intensity.
- Similarly, adding intercanopy lighting at the higher total intensity enabled a less aggressive pruning strategy that, in combination with the higher light intensity, also increased the cumulative number of cucumber fruits in both cultivars up to 53% compared to the top light-only treatment at the lower intensity.
- Both cucumber cultivars also saw a decrease in total plant height and more compact morphology at the higher intensity treatments.
- Adding intercanopy lighting at the higher total intensity also increased cumulative yield and the total number of fruits up to 62% and 57%, respectively, in both tomato cultivars over the top light-only treatment at the lower intensity.
To ensure high-quality crops year-round, cucumber and tomato greenhouse growers often explore supplemental lighting strategies to adequately light plants during darker fall and winter months. With Fluence and WUR’s latest intercanopy lighting research, growers can now consider additional light distribution options to optimize yield and quality to meet their cultivation goals.
For more information on Fluence and its ongoing research initiatives, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom